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Abstract
Mitochondria are organelles with recognized key roles in cellular homeostasis,
including bioenergetics, redox, calcium signaling, and cell death. Mitochondria are
essential for neuronal function, given the high energy demands of the human brain.
Consequently, mitochondrial diseases affecting oxidative phosphorylation (OXPHOS)
commonly exhibit neurological impairment. Emerging evidence suggests that mito-
chondria are important not only for mature postmitotic neurons but also for the regu-
lation of neural progenitor cells (NPCs) during the process of neurogenesis. These
recent findings put mitochondria as central regulator of cell fate decisions during
brain development. OXPHOS mutations may disrupt the function of NPCs and
thereby impair the metabolic programming required for neural fate commitment. Pro-
moting the mitochondrial function of NPCs could therefore represent a novel inter-
ventional approach against incurable mitochondrial diseases.
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Significance statement
This study discusses the emerging role of mitochondria for neural progenitor cells and for the
regulation of cell fate decisions during neurogenesis. Elucidating the importance of mitochondria
in neurogenesis might be instrumental to identify interventional targets for mitochondrial dis-
eases, a group of rare incurable disorders causing neurological and neurodevelopmental defects.
1 | INTRODUCTION
Mitochondria are dynamic double-membrane organelles that are
classically considered to be the powerhouse of the cell for their
production of adenosine triphosphate (ATP) through the process
of oxidative phosphorylation (OXPHOS).1 At the same time, mito-
chondria are involved in several additional tasks, including calcium
and free radical signaling, apoptosis, and metabolite-mediated
modulation of gene expression.2 Hence, mitochondria can act as
gatekeepers of cellular homeostasis and can regulate cell death
pathways to preserve cellular fitness and maintain genome
integrity.3,4
In the past few years, several works investigated the role of mito-
chondria in stem cell reprogramming and differentiation.5-7
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Undifferentiated stem cells mainly rely on glycolytic metabolism for energy
generation and exhibit mitochondria with a roundish morphology.8 During
the differentiation process, mitochondria acquire a fused morphology and
the metabolism switches from glycolysis to OXPHOS.9,10 Conversely,
somatic cells generally depend on OXPHOS and show a fused mitochon-
drial network, which reverts to a stem cell-like state upon reprogramming
into induced pluripotent stem cells (iPSCs).9,11,12
Among somatic cells, neurons are known to be highly dependent
on mitochondrial function, given the high energy demand of the brain,
which consumes around 20% of energy at rest despite weighting only
around 2% of the entire human body.13 Recent evidence indicates
that mitochondria could play a role not only in energetically demand-
ing mature cells like neurons, but also in governing cell fate decisions
during the establishment of physiological neurogenesis.14-17
Here, we focus on the emerging role of mitochondria for neuro-
genesis and for the function of neural progenitor cells (NPCs). We dis-
cuss the impact of these recent findings in the context of mitochondrial
diseases. Mitochondrial diseases are currently incurable and the mecha-
nisms underlying their neuronal pathology remain to be fully understood.
2 | MITOCHONDRIA IN CELL FATE
DECISION: BIOENERGETICS AND BEYOND
The OXPHOS process occurs at the level of the mitochondrial inner
membrane through five membrane protein complexes. As mitochon-
drial complexes shuttle electrons from one to another, protons are
pumped into the inner mitochondrial matrix. This creates a proton gra-
dient along the inner mitochondrial membrane, known as mitochon-
drial membrane potential (MMP).18 The release of protons through
the mitochondrial complex V, and their conversion into water in the
presence of oxygen, enables the final generation of ATP.19
Mitochondria dynamically regulate their structural morphology
through fusion or fission of the outer and inner mitochondrial mem-
brane in a coordinated manner.20 This is orchestrated by the
dynamin-related GTPases Mitofusin 1 (MFN1), Mitofusin 2 (MFN2),
optic atrophy protein 1 (OPA1), and Dynamin-related protein
1 (DRP1).21,22 Also cristae membranes, once thought to be static
under physiological conditions, can rapidly reshape their ultrastruc-
tural morphology.23 The coordinated modifications of mitochondrial
shape and cristae architecture can play a critical role in the cellular
regulation of bioenergetic outputs and in the cellular adaptation to
environmental cues and changing demands.24,25
OXPHOS is under dual genetic control.26 The majority of mito-
chondrial complex proteins are encoded by the nuclear DNA, while
13 protein subunits are encoded by the mitochondrial DNA
(mtDNA). mtDNA, a circular 16.5 kb-long genome, also encodes
two rRNAs and 22 tRNAs for mtDNA translation.27 mtDNA does
not exhibit introns or histones, and it is present in multiple copies
in mammalian cells. When an mtDNA mutation occurs, the muta-
tion can be present in all mtDNA molecules (a situation known as
homoplasmy) or only in a portion of the mtDNA molecules
(a situation known as heteroplasmy).28 Since mtDNA is inherited
through the maternal lineage, mtDNA mutations can be passed
from mother to offspring. However, the proportion of mutated
molecules can vary dramatically among the children. This phenome-
non is usually explained by the so-called mtDNA bottleneck, that is,
the presence of a sudden reduction of mtDNA copies from primor-
dial germ cells during the production of primary oocytes that
changes the ratio between mutated and wild-type mtDNA mole-
cules.29 For this reason, a healthy mother carrying mtDNA muta-
tions at low heteroplasmy could give birth to healthy children with
low levels of heteroplasmy, as well as to affected children carrying
pathogenically high levels of heteroplasmy.
The number of mtDNA copies can also vary among individual
cells. Energetically demanding cells like neurons and cardiomyocytes
possess elevated mtDNA copy number, while less active cells usually
exhibit low amount of mtDNA copies. Undifferentiated stem cells
usually contain low mtDNA copy number, which gradually increases
during differentiation.9,30 A major mechanism governing mtDNA
copy number in cells is nuclear transcription-mediated mitochondrial
biogenesis.31 The master regulator of mitochondrial biogenesis is
PPAR-gamma Coactivator 1 alpha (PGC-1a), a transcriptional
coactivator induced in the cells by shortage of energy or by
increased energy demands.32,33 Low ATP levels are sensed by AMP-
dependent kinase (AMPK), which responds by switching on
mechanisms to increase energy output, including PGC-1a. AMPK can
activate PGC-1a through SIRT1-mediated deacetylation or through
direct phosphorylation.34,35 Once activated, PGC-1a induces nuclear
respiratory factors (NRF1 and NRF2) to promote the expression of
OXPHOS-related genes.36
Besides bioenergetics, mitochondria perform a plethora of func-
tions that contribute to the regulation of cellular homeostasis. Mito-
chondria are involved in the generation of reactive oxygen species
(ROS), calcium balance, and apoptotic cells death.3,37 ROS and calcium
are important second messengers involved in cellular signaling.38
However, excessive ROS production that cannot be counterbalanced
by the antioxidant capacity of the cell can result in macromolecular
damage.39 Similarly, disproportionate intramitochondrial accumulation
of calcium can cause the opening of the mitochondrial permeability
transition pore, leading to the collapse of the MMP and the initiation
of the apoptotic cascade.40 In the context of stem cells, ROS are impli-
cated in promoting differentiation through activation of a nuclear
transcriptional program that alters gene expression profiles.41-43
Indeed, ROS mediated damage and antioxidant levels increase during
stem cell differentiation and decrease upon reprogramming to
iPSCs.9,44
Mitochondrial metabolites generated in the mitochondria
through the tricarboxylic (TCA) cycle can also function as cofac-
tors or substrates for chromatin modifying enzymes. Hence, the
amount of mitochondrial activity and related levels of metabolites
can influence the global epigenetic landscape of the cells through
the regulation of nuclear gene expression.45 Through this
crosstalk between energy metabolism and gene regulation, mito-
chondrial activity can thus contribute to the regulation of cell fate
identity and plasticity.6
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3 | MITOCHONDRIA IN NEUROGENESIS
Of all cell types in the central nervous system (CNS), neurons have
the highest energy demands.46 The majority of ATP generated in the
CNS is utilized to maintain neuronal excitability and overall synaptic
function.47 In order to maximize local energy generation, mitochondria
can be anchored at dendrites and synapses to synthetize ATP, thereby
fueling vesicle recycling during neuronal activity.48 However, in addi-
tion to postmitotic neurons, mitochondrial OXPHOS might also play a
crucial role during neurogenesis.16,49
Neurogenesis is the process in which new neurons are formed from
NPCs.50,51 NPCs can be defined as the precursor cell population in the
CNS giving rise to neuronal cells and glial cells that include oligodendro-
cytes and astrocytes.52 Importantly, mammalian NPCs can be present
not only during embryonic brain development,53 but also in neonatal and
mature adult brain.51,54 However, to what extent neurogenesis is
maintained during human adulthood still remains a matter of debate.55-57
In the process of generating neurons, the metabolic program
undergoes critical changes. Undifferentiated stem cells mainly rely on
glycolysis,9,58 while neurons are highly dependent on mitochondrial
OXPHOS.59 Single-cell transcriptomics of adult mouse NPCs revealed
the activation of an OXPHOS signature during the initiation of neuro-
genesis.60 The acquisition of such metabolic program could represent
an important factor for the evolution of the human brain size.61 The
human brain contains an expanded pool of progenitors compared to
rodents, which could contribute to the extension of brain size, and
exhibit higher basal energy expenditures compared to primates, which
might provide sufficient energy for larger brains and faster reproduc-
tion while maintaining homeostatic functions and longevity .61
In order to acquire an OXPHOS metabolic profile, mitochondria in
differentiating neuronal cells increase in number, and develop an elon-
gated morphology with a dense network appearance.62,63 During
mouse embryonic neurogenesis, mitochondria in intermediate progeni-
tor cells appear more fragmented than in undifferentiated neural stem
cells.64 Conversely, in adult neurogenesis mitochondria in intermediate
progenitor cells show increased fused morphology compared to
undifferentiated neural stem cells.65 Despite these minor differences, it
is widely accepted that mitochondria undergo changes during neuro-
genesis to eventually acquire an elongated morphology in neurons.15,17
Until recently, the above-mentioned changes in energy metabo-
lism and mitochondrial morphology were considered as one of the by-
products of neuronal differentiation, together with changes in cell
cycle, communication, and signaling.15,66 However, recent data in
mouse embryonic NPCs and human iPSC-derived NPCs reveled that
changes in mitochondrial dynamics are instrumental in initiating neu-
rogenesis.14 During cell division, NPCs can either self-renew or exit
from stemness to begin neuronal differentiation. Interestingly, those
NPCs with fragmented mitochondria are the ones that are poised to
become neurons, while those with fused mitochondria are destined
to self-renew and maintain stemness.14 The time window for this
decision point was found to be 3 to 6 hours for mouse NPCs and 6 to
12 hours for human NPCs.14 These new findings provide a causal link
between mitochondrial remodeling and mammalian neurogenesis,
suggesting new potential targets for neurological diseases in which
mitochondrial function is impaired.
In agreement with this new role of mitochondrial dynamics in
instructing neurogenesis, recent works highlighted the importance of mito-
chondrial metabolism for neurogenesis. Adult neurogenesis requires mito-
chondrial activity, as proliferating mouse intermediate progenitors become
dependent on OXPHOS, and OXPHOS disruption in mice can induce pre-
mature aging phenotypes.65,67 Indeed, human iPSC-derived NPCs exhibit
fused mitochondria, and a reduction of glycolytic metabolism coupled with
increased OXPHOS.68 Proliferating mouse adult NPCs also express high
endogenous ROS levels, suggestive of elevated mitochondrial activity.69
Redox regulation impacts physiological neurogenesis,69 and may play a
role in NPCs for balancing between stemness and differentiation.70
Increasing the glycolytic reliance of NPCs can prevent their neuronal com-
mitment, as seen for example in mouse embryonic NPCs expressing low
levels of the RNA-binding protein Sam68.71 Accordingly, the impairment
of mitochondrial function in mouse embryonic NPCs causes calcium
dyshomeostasis and delayed cortical neurogenesis.72 Inhibition of mito-
chondrial function also disrupt the generation of neurons from human
embryonic stem cells.73
Mitochondrial function may not only be crucial for the activity
and survival of postmitotic neurons and for safeguarding the ability of
NPCs to commit to neuronal cell fate, but also for ensuring the physi-
ological homeostasis of NPCs (Figure 1). Mitochondrial function in
embryonic and adult mice was found essential not only for ensuring
proper NPC differentiation but also for allowing their maintenance of
self-renewing capacity.74 Two recent studies identified that two pro-
teins that are crucial for neurogenesis, and specifically for neocortex
expansion, namely MCPH1 and ARHGAP11B, act in the mitochondria
of NPCs.75,76 Hence, the mitochondrial function of NPCs may play a
pivotal role for mammalian neurogenesis and neocortical growth.77
For the proper generation of neurons, which are highly complex
and polarized cells, it is essential to establish a proper morphology for
dendrites, axons, and synapses. This process is known as neuronal
morphogenesis.78 Mitochondria may play an important role during
neuronal morphogenesis.79 Mitochondria are present at synaptic ter-
minals during the time synaptic connections are formed.80,81 Mito-
chondria also contribute to the coordination of axon branching sites
through localized axonal protein synthesis.82 Depletion of mitochon-
dria during neuronal morphogenesis can lead to defects in synaptic
plasticity and spine morphology.48,83
Taken together, dysfunctions in the regulation of mitochondrial
dynamics and morphology or defective OXPHOS bioenergetics could
have profound effects on physiological neurogenesis and on the
proper establishment of neuronal function.
4 | NEURAL PROGENITOR CELLS AS
POTENTIAL INTERVENTIONAL TARGETS
FOR MITOCHONDRIAL DISEASES
One of the major causes of mitochondrial dysfunction in humans is
represented by mitochondrial diseases, a group of rare genetic
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disorders caused by mutations in nuclear DNA genes or mtDNA genes
encoding for proteins involved in OXPHOS functionality and struc-
tural assembly, mtDNA replication, mitochondrial transcription and
translation, and mitochondrial dynamics.26,84 Mitochondrial diseases
affect approximately 1 in 4000 newborns, and typically cause neuro-
logical symptoms including psychomotor regression, stroke-like epi-
sodes, dementia, and epilepsy (Table 1).84,85 Not only is the CNS a
major target in primary genetically determined mitochondrial diseases,
but mitochondrial dysfunction is also a prominent feature in many of
the most prevalent neurodegenerative diseases.86
Although in the past 30 years mitochondrial medicine has made
enormous progresses in understanding the genetic and biochemical
pathomechanisms of mitochondrial disorders,87,88 current treatments
still remain focused on controlling complications and reducing the
symptoms.89,90 The lack of effective therapies for most mitochondrial
diseases is due to several problems, including a specific lack of effec-
tive preclinical models for performing drug discovery.91 The lack of
disease models has limited the identifications of adequate markers
and useful clinical outcomes, and it also prevented a more detailed
understanding of the mechanisms underlying the neuronal pathology
associated with mitochondrial diseases.
Based on the current mechanistic understanding, the neurological
defects caused by mitochondrial diseases are mainly attributed to the
degeneration of postmitotic neurons.84,85 However, given the above-
mentioned studies implicating mitochondria in the homeostatic
regulation of NPCs and neurogenesis, it is possible that NPCs dys-
function may play an important yet underappreciated contributing
role in the development of mitochondrial diseases. Accordingly, mito-
chondrial diseases can exhibit neurodevelopmental manifestations,
such as developmental delay and cognitive impairment.92-94
The use of patient-derived iPSCs is providing important new
insights that can shed light on the role of NPCs in the neuronal patho-
genesis of mitochondrial diseases. NPCs generated from patients with
mitochondrial diseases carrying mutations associated with Leigh syn-
drome (LS) in the mtDNA gene MT-ATP6 (mitochondrially encoded
ATP synthase membrane subunit 6) exhibited defective OXPHOS bio-
energetics and aberrant calcium homeostasis.68,95 Cerebral organoids
derived from LS patients carrying mutations in the mtDNA gene MT-
ATP6 or in the nuclear genes PDH (pyruvate dehydrogenase) or DLD
(dihydrolipoyl dehydrogenase) showed thinner neuronal cortical layers
and abnormal organization of progenitor cells, indicative of defective
neurogenesis.96 A spinal cord organoid system obtained from patient-
specific iPSCs carrying the A3243G mutation in the mtDNA gene MT-
TL1 (mitochondrially encoded TRNA-Leu [UUA/G] 1) associated with
the mitochondrial disease MELAS (mitochondrial encephalomyopathy,
lactic acidosis, and stroke-like episodes) also exhibited delayed neuro-
genesis and neurite outgrowth defects.97 The distribution of NPCs
was affected in cerebral organoids carrying LS-related mutations in
the nuclear gene SURF1 (Surfeit locus protein 1).98 Indeed patient
organoids displayed a loss of neurogenic progenitor zones, which
F IGURE 1 Mitochondrial pathways in cell fate decisions and neurogenesis. Mitochondria undergo changes during the commitment and
differentiation of neural progenitor cells (NPCs). We here depict some of these changes highlighting distinct functions and mechanisms in
different colors. MMP, mitochondrial membrane potential; ROS, reactive oxygen species
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TABLE 1 Neurological mitochondrial diseases
Mitochondrial disease Main neurological symptoms Mutated genes Mitochondrial dysfunction
Leigh syndrome (LS) Psychomotor regression,
seizures, breathing problems,
hypotonia, ataxia, lactic acidosis
NDUFS1, NDUFS3, NDUFS4, NDUFS7, NDUFS8,
NDUFA2, NDUFA9, NDUFA10, NDUFA12, NDUFV1,








EFG1 Multiple RC complexes


















EARS2 Multiple RC complexes
Leukoencephalopathy with










NDUFS1, NDUFV1, NUBPL Complex I
SDHAF1, SDHA, SDHB Complex II
LYRM7 Complex III
COX6B1, SURF1, APOPT1 Complex IV
PDHA1 PDH
EF-Tu, MPV17 Multiple RC complexes
NFU1, BOLA3, IBA57, ISCA2 Multiple RC complexes
Leber's hereditary optic
neuropathy (LHON)
Vision loss MT-ND1, MT-ND4, MT-ND5, MT-ND6 Complex I
Kearns-Sayre syndrome
(KSS)














A8344G, T8356C Multiple RC complexes
Maternal inherited Leigh
syndrome (MILS)




Neuropathy, ataxia, vision loss MT-ATP6 (low heteroplasmy) Complex V
Alpers disease (MSD4A) Seizures, dementia, spasticity,
blindness
POLG1 Isolated or multiple RC
complexes
(Continues)
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formed around cavities resembling embryonic-like ventricles in
healthy organoids.98 The NPC defects found in SURF1-mutant human
organoids are in agreement with findings in SURF1 knockout piglets,
which displayed significant reduction of the cortical thickness of the
cerebral cortex gray matter at early postnatal ages and a disorganized
cortical structure.99
TABLE 1 (Continued)














MPV17 dNTP pool imbalance
Charcot Marie Tooth
(CMT2A)
Peripheral neuropathy MFN2 Bioenergetic defects
Dominant optic atrophy
(DOA)
Optic nerve degeneration OPA1 Bioenergetic defects
Encephalopathy due to












PITRM1 MTS and Aβ processing
defect






CoQ2, CoQ4, CoQ9, PDSS1, PDSS2, CABC1, ADCK3 Bioenergetic defects
F IGURE 2 Metabolic programming during neurogenesis as a target for disease intervention. Left: In healthy conditions (above), there is an
orchestrated programming of energy metabolism during the generation of neurons from pluripotent stem cells (PSCs), as neural progenitor cells (NPCs)
start to shift toward oxidative phosphorylation (OXPHOS) and away from glycolysis. In patients with mitochondrial diseases (below), the metabolic shift
to OXPHOS may be impaired, leading to improper generation of neurons that fail to mature and fail to generate the needed branches and connections.
These NPCs defects may represent a potential target for disease intervention strategies aiming at reestablishing physiological neurogenesis. Right: An
example of interventional strategies may be represented by the pharmacological activation of PGC-1a, which could promote the OXPHOS shift in
NPCs by increasing mitochondrial biogenesis, ultimately leading to improved generation and maturation of neurons
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These findings collectively suggest that mutations associated with
mitochondrial diseases could impair neurogenesis by disrupting the
physiological function of NPCs. In particular, mitochondrial defects
may prevent the establishment of the OXPHOS metabolic program of
NPCs, which is necessary for orchestrating mammalian neurogenesis
(see chapter above). NPCs from mitochondrial patients might not be
able to shift their metabolism to OXPHOS, thereby causing a failure
to commit to mature neurons (Figure 2). In addition, mitochondrial
defects could hamper the establishment of neuronal morphogenesis
and synaptogenesis that are essential for physiological brain develop-
ment (see chapter above). Indeed, early neurons generated from
patient-derived NPCs carrying SURF1 mutations exhibited reduced
branching outgrowth capacity and functional synaptic deficits.98
These developmental-related disruptions in neurogenesis and mor-
phogenesis might potentially explain the cognitive impairment that
can be observed in mitochondrial patients.92 Hence, the mitochondrial
state of NPCs may potentially represent an innovative target for inter-
ventional strategies aiming at reestablishing the physiological process
of metabolic programming and the consequent instruction of human
neurogenesis (Figure 2).
One potential treatment strategy targeting NPCs could be to use
measures capable of promoting their metabolic shift toward OXPHOS.
For example, pharmacological activation of PGC-1a might be
exploited to activate mitochondrial biogenesis, which in turn may
improve the mitochondrial bioenergetic output of NPCs, thereby
enhancing their ability to commit to neuronal fate and grow complex
branches (Figure 2). Accordingly, genetic overexpression of PGC-1a or
pharmacological activation of PGC-1a using the drug bezafibrate pro-
moted OXPHOS metabolism in patient-derived NPCs carrying SURF1
mutations, leading to improved neuronal branching formation in
nascent neurons.98 Genetic overexpression of PGC-1a in Surf1 knock-
out mice also enhanced OXPHOS activity and improved motor abili-
ties.100 PGC-1a activation may promote synaptogenesis also by
supporting astrocyte maturation.101 Treating human and mouse NPCs
with an inductor of oxidative metabolism (called α5 mixture) com-
posed by TCA cycle precursors and amino acids, also led to increased
branching outgrowth and neuronal maturation.102
This shifted view of therapeutic approaches to mitochondrial dis-
eases might lead to novel interventions aiming at promoting the
reestablishment of physiological neurogenesis rather than merely
preventing the degeneration of mature neurons. The interpretation that
the neuronal pathology of mitochondrial diseases is caused by neu-
rodegeneration influenced treatment schemes centered on antioxidants
to prevent the buildup of damaging ROS.87 However, antioxidants, which
may dampen physiological ROS signaling,103 failed to consistently
improve the patient symptomatology.88,90 Conversely, gene augmenta-
tion therapy based on the expression of a healthy copy of SURF1 in
patient NPCs improved early neuronal morphogenesis.98 These latter
results suggest that, at least in this case, the neuronal pathology of mito-
chondrial diseases might be caused by loss of function defects affecting
neurogenesis that could be potentially restored if targeted early on.
Taken together, mitochondrial function may be crucial for the
homeostasis and commitment of NPCs during the establishment of
neurogenesis. We suggest that innovative strategies of intervention
against disorders impairing mitochondrial function could thus focus on
enhancing the OXPHOS metabolic program of NPCs in order to promote
neurogenesis and the downstream generation of functional neurons.
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